Find Eribulin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

API REF. PRICE (USD/KG)

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Halaven, Eribulin mesilate, 441045-17-6, Eribulin (mesylate), Eribulin mesylate [usan], Eribulin (as mesylate)
Molecular Formula
C41H63NO14S
Molecular Weight
826.0  g/mol
InChI Key
QAMYWGZHLCQOOJ-WRNBYXCMSA-N
FDA UNII
AV9U0660CW

Eribulin
Eribulin Mesylate is the mesylate salt of a synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.
1 2D Structure

Eribulin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one;methanesulfonic acid
2.1.2 InChI
InChI=1S/C40H59NO11.CH4O3S/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41;1-5(2,3)4/h19,23-39,43H,2-3,5-18,41H2,1,4H3;1H3,(H,2,3,4)/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+;/m1./s1
2.1.3 InChI Key
QAMYWGZHLCQOOJ-WRNBYXCMSA-N
2.1.4 Canonical SMILES
CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O.CS(=O)(=O)O
2.1.5 Isomeric SMILES
C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O.CS(=O)(=O)O
2.2 Other Identifiers
2.2.1 UNII
AV9U0660CW
2.3 Synonyms
2.3.1 MeSH Synonyms

1. B 1793

2. B 1939

3. B-1793

4. B-1939

5. E 7389

6. E-7389

7. Er 086526

8. Er-086526

9. Er-86526

10. Er086526

11. Eribulin

12. Eribulin (as Mesylate)

13. Eribulin Mesilate

14. Eribulin Monomethanesulfonate

15. Halaven

16. Nsc 707389

17. Nsc-707389

18. Nsc707389

2.3.2 Depositor-Supplied Synonyms

1. Halaven

2. Eribulin Mesilate

3. 441045-17-6

4. Eribulin (mesylate)

5. Eribulin Mesylate [usan]

6. Eribulin (as Mesylate)

7. E7389

8. Eribulin Monomethanesulfonate

9. Av9u0660cw

10. Chebi:70710

11. E 7389

12. E-7389

13. Eribulin Mesilate (jan)

14. Eribulin Mesylate (usan)

15. B-1939

16. (1s,3s,6s,9s,12s,14r,16r,18s,20r,21r,22s,26r,29s,31r,32s,33r,35r,36s)-20-[(2s)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one;methanesulfonic Acid

17. Eribulin Mesilate [jan]

18. Nsc-707389

19. Er-086526

20. Unii-av9u0660cw

21. Halaven (tn)

22. B1939 Mesylate

23. E7389 Mesylate

24. Er-086526 Mesylate

25. Chembl1683544

26. Eribulin Mesylate [vandf]

27. Eribulin Mesilate [mart.]

28. Eribulin Mesilate [who-dd]

29. Ex-a4873

30. Eribulin Mesylate [ema Epar]

31. Hy-13442a

32. Eribulin Mesylate [orange Book]

33. Eribulin Monomethanesulfonate [mi]

34. D08914

35. Q27882076

36. B1939 Mesylate; E7389 Mesylate; Er-086526 Mesylate

37. (2r,3r,3as,7r,8as,9s,10ar,11s,12r,13ar,13bs,15s,18s,21s,24s,26r,28r,29as)-2-((2s)-3-amino-2-hydroxypropyl)-3-methoxy-26-methyl-20,27-dimethylidenehexacosahydro-11,15:18,21:24,28-triepoxy-7,9-ethano-12,15-methano-9h,15h-furo(3,2-i)furo(2',3':5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5(4h)-one Methanesulfonate (salt)

38. 11,15:18,21:24,28-triepoxy-7,9-ethano-12,15-methano-9h,15h-furo(3,2-i)furo(2',3':5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5(4h)-one, 2-((2s)-3- Amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-, 2r,3r,3as,7r,8as,9s,10ar,11s,12r,13ar,13bs,15s,18s,21s,24s,26r,28r,29as)-, Methanesulfonate (salt)

39. 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9h,15h-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4h)-one Methanesulfonate

2.4 Create Date
2007-11-26
3 Chemical and Physical Properties
Molecular Weight 826.0 g/mol
Molecular Formula C41H63NO14S
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count15
Rotatable Bond Count4
Exact Mass825.39692686 g/mol
Monoisotopic Mass825.39692686 g/mol
Topological Polar Surface Area209 Ų
Heavy Atom Count57
Formal Charge0
Complexity1470
Isotope Atom Count0
Defined Atom Stereocenter Count19
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameHalaven
PubMed HealthEribulin (Injection)
Drug ClassesAntineoplastic Agent
Drug LabelHALAVEN (eribulin mesylate) Injection is a non-taxane microtubule dynamics inhibitor. Eribulin mesylate is a synthetic analogue of halichondrin B, a product isolated from the marine sponge Halichondria okadai. The chemical name for eribulin mesyl...
Active IngredientEribulin mesylate
Dosage FormSolution
RouteIntravenous
Strength1mg/2ml (0.5mg/ml)
Market StatusPrescription
CompanyEisai

2 of 2  
Drug NameHalaven
PubMed HealthEribulin (Injection)
Drug ClassesAntineoplastic Agent
Drug LabelHALAVEN (eribulin mesylate) Injection is a non-taxane microtubule dynamics inhibitor. Eribulin mesylate is a synthetic analogue of halichondrin B, a product isolated from the marine sponge Halichondria okadai. The chemical name for eribulin mesyl...
Active IngredientEribulin mesylate
Dosage FormSolution
RouteIntravenous
Strength1mg/2ml (0.5mg/ml)
Market StatusPrescription
CompanyEisai

4.2 Drug Indication

Halaven monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease (see section 5. 1). Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.

Halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see section 5. 1).


5 Pharmacology and Biochemistry
5.1 FDA Pharmacological Classification
5.1.1 Pharmacological Classes
Microtubule Inhibitor [EPC]; Microtubule Inhibition [PE]
5.2 ATC Code

L01XX41


API SUPPLIERS

read-more
read-more

01

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
Dr Reddy Company Banner

02

Transo-Pharm USA LLC

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF US arrow-down AUDIT
Transo Pharm USA Company Banner

03

Shanghai Minbiotech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Shanghai Minbiotech CB

04

ChemExpress

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & novel modalities with ICH-grade quality.

Flag China
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF ASMF arrow-down AUDIT
Company Banner

05

Sigma-Aldrich Corporation

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
Company Banner

06

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Dr Reddy Company Banner

07

Jiangsu Zenji Pharmaceuticals,Ltd.

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

EPSC
Not Confirmed
arrow

Jiangsu Zenji Pharmaceuticals,Ltd.

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
EPSC
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Jiangsu Zenji Pharmaceuticals,Ltd.

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

EPSC
Not Confirmed
arrow

Jiangsu Zenji Pharmaceuticals,Ltd.

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
EPSC
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

Jiangsu Zenji Pharmaceuticals,Ltd.

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

EPSC
Not Confirmed
arrow

Jiangsu Zenji Pharmaceuticals,Ltd.

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
EPSC
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Chongqing Sintaho Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

EPSC
Not Confirmed
arrow

Chongqing Sintaho Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
EPSC
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1753727400,"product":"PHARMACEUTICAL RAW MATERIAL ERIBULIN MESYLATE BATCH NO.: 5EBM425002 MFG. DATE: 31 MAY 2025 RETEST DATE:30 MAY 20","address":"T-184, MIDC, BHOSARI,","city":"PUNE-MAHARASHTRA","supplier":"EMCURE PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"TEHRAN","customer":"NANO FANAVARAN DAROUEI ALVAND CO","customerCountry":"IRAN","quantity":"0.01","actualQuantity":"0.005","unit":"KGS","unitRateFc":"21500000","totalValueFC":"103900.6","currency":"USD","unitRateINR":1788460187.9999998,"date":"29-Jul-2025","totalValueINR":"8942300.94","totalValueInUsd":"103900.6","indian_port":"Bombay Air","hs_no":"29321990","bill_no":"3984733","productDescription":"API","marketType":"","country":"IRAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"T-184, MIDC, BHOSARI,, PUNE-MAHARASHTRA","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1650220200,"product":"ERIBULIN MESYLATE API 19978405REST","address":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3","city":"","supplier":"BAXTER ONCOLOGY GMBH","supplierCountry":"GERMANY","foreign_port":"FRANKFURT AM MAIN","customer":"SYNGENE INTERNATIONAL LTD UNIT VII POD 3","customerCountry":"INDIA","quantity":"0.01","actualQuantity":"10","unit":"GMS","unitRateFc":"35850","totalValueFC":"364919.7","currency":"USD","unitRateINR":"2753280","date":"18-Apr-2022","totalValueINR":"27532800","totalValueInUsd":"364919.7","indian_port":"Biocon-SEZ","hs_no":"29329990","bill_no":"1005293","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"FRANKFURT AM MAIN","supplierAddress":"KANTSTR.2 HALLE\/WESTFALEN HALLE 33790 DE","customerAddress":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1650997800,"product":"ERIBULIN INTERMEDIATE N-2 (CHEMICAL NAME :((2R,3R,3AS,7R,8AS,9S,10AR,11S,12R,13AR,13BS,15S,18S,21S, 24S,26R,28R,29AS)-","address":"SHOP-37, FIRST FLR. KAMLA BHAVAN I I,S. NITYANAND ROAD ANDHERI EAST","city":"MUMBAI,MAHARASHTRA","supplier":"BRIGHTGENE BIO MEDICAL TECHNOL","supplierCountry":"CHINA","foreign_port":"NA","customer":"GUFIC BIOSCIENCES LTD","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"4","unit":"GMS","unitRateFc":"12000","totalValueFC":"49082.2","currency":"USD","unitRateINR":"925800","date":"27-Apr-2022","totalValueINR":"3703200","totalValueInUsd":"49082.2","indian_port":"MADRAS AIR","hs_no":"29339990","bill_no":"8449808","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"SHOP-37, FIRST FLR. KAMLA BHAVAN I I,S. NITYANAND ROAD ANDHERI EAST"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1678645800,"product":"ERIBULIN MESYLATE","address":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3","city":"","supplier":"WISDOM PHARMACEUTICAL CO LTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"SYNGENE INTERNATIONAL LTD UNIT VII POD 3","customerCountry":"INDIA","quantity":"0.01","actualQuantity":"8","unit":"GMS","unitRateFc":"37227","totalValueFC":"302340.7","currency":"USD","unitRateINR":"3108454.5","date":"13-Mar-2023","totalValueINR":"24867636","totalValueInUsd":"302340.7","indian_port":"Biocon-SEZ","hs_no":"29213090","bill_no":"1003500","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"N\/A","customerAddress":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1725042600,"product":"ERIBULIN INTERMEDIATE N-2 (4 GRAMS)CHEMICAL NAME: (2R,3R,3AS,7R,8AS,9S,10AR,11S,12R,13AR,1 3BS,15S,18S,21S, 24S,26R,28R,","address":"2NF FLOOR,BUILDING A,","city":"ANDHERI[W],MUMBAI,","supplier":"BRIGHTGENE BIO MEDICAL TECHNOLOGY CO LTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"GUFIC BIOSCIENCES LTD","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"4","unit":"GMS","unitRateFc":"5500","totalValueFC":"22254.8","currency":"USD","unitRateINR":"466675","date":"31-Aug-2024","totalValueINR":"1866700","totalValueInUsd":"22254.8","indian_port":"Madras Air","hs_no":"29339990","bill_no":"5347606","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"BUILDING C26 NO 218 XINGHU ROAD SUZHOU I NDUSTRIAL PARK SUZHOU JIANGSU215000 CHI NA CHINA","customerAddress":"2NF FLOOR,BUILDING A,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1726425000,"product":"ERIBULIN INTERMEDIATE N-6 (0.0001 KGS)","address":"T-184, MIDC, BHOSARI,","city":"PUNE-MAHARASHTRA","supplier":"WUYAN PHARMACEUTICAL TECHNOLOGY SHANGHAI COLTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"EMCURE PHARMACEUTICALS LTD","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.0001","unit":"KGS","unitRateFc":"6000000","totalValueFC":"607.9","currency":"USD","unitRateINR":"509400000","date":"16-Sep-2024","totalValueINR":"50940","totalValueInUsd":"607.9","indian_port":"Bombay Air","hs_no":"29321990","bill_no":"5629119","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"BUILDING 22 , NO.8666,HUNAN HIGHWAY , PUDONG NEW DISTRICT SHANGHAI, P.R .CHINA 201314 Shanghai, , China China","customerAddress":"T-184, MIDC, BHOSARI,"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1749666600,"product":"ERIBULIN INTERMEDIATE N-6 [QTY : 0.121 KGS] ERIBULIN INTERMEDIATE N-6 [QTY : 0.121 KGS]","address":"T-184, MIDC, BHOSARI,","city":"PUNE-MAHARASHTRA","supplier":"ZENJI PHARMACEUTICALS SU ZHOU LTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"EMCURE PHARMACEUTICALS LTD","customerCountry":"INDIA","quantity":"0.12","actualQuantity":"0.121","unit":"KGS","unitRateFc":"1000000","totalValueFC":"122161.2","currency":"USD","unitRateINR":"86750000","date":"12-Jun-2025","totalValueINR":"10496750","totalValueInUsd":"122161.2","indian_port":"Bombay Air","hs_no":"29321990","bill_no":"2612432","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"122XUQING ROAD, XUGUAN TOWN, SUZHOU , JIANGSU, CHINA 215151 Suzhou, , C hina China","customerAddress":"T-184, MIDC, BHOSARI,"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1751049000,"product":"ERIBULIN INTERMEDIATE N-6 ERIBULIN INTERMEDIATE N-6","address":"T-184, MIDC, BHOSARI,","city":"PUNE-MAHARASHTRA","supplier":"WUYAN PHARMACEUTICAL TECHNOLOGY SHANGHAI COLTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"EMCURE PHARMACEUTICALS LTD","customerCountry":"INDIA","quantity":"0.01","actualQuantity":"0.01","unit":"KGS","unitRateFc":"1200000","totalValueFC":"12240.8","currency":"USD","unitRateINR":"105180000","date":"28-Jun-2025","totalValueINR":"1051800","totalValueInUsd":"12240.8","indian_port":"Bombay Air","hs_no":"29321990","bill_no":"2938289","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"PUDONG NEW AREA BUILDING 22, NO.866 6,SHANGHAI 20134 Shanghai, , China SDNF China","customerAddress":"T-184, MIDC, BHOSARI,"}]
18-Apr-2022
29-Jul-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Eribulin EVER Pharma is a microtubule inhibitor which is indicated for the treatment of locally advanced or metastatic breast cancer and unresectable liposarcoma.


Lead Product(s): Eribulin,Inapplicable

Therapeutic Area: Oncology Brand Name: Eribulin EVER Pharma

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 16, 2024

Ever Pharma CB

01

Ever Pharma

Austria
arrow

Lead Product(s) : Eribulin,Inapplicable

Therapeutic Area : Oncology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Eribulin EVER Pharma is a microtubule inhibitor which is indicated for the treatment of locally advanced or metastatic breast cancer and unresectable liposarcoma.

Product Name : Eribulin EVER Pharma

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 16, 2024

Ever Pharma CB

02

EPSC
Not Confirmed

03

EPSC
Not Confirmed

Details:

Eribulin Mesylate, a non-taxane microtubule dynamics inhibitor used for the treatment of breast cancer, is expected to be the first generic approval on the market.


Lead Product(s): Eribulin,Inapplicable

Therapeutic Area: Oncology Brand Name: Eribulin Mesylate-Generic

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 04, 2024

blank

04

EPSC
Not Confirmed
EPSC
Not Confirmed

Details : Eribulin Mesylate, a non-taxane microtubule dynamics inhibitor used for the treatment of breast cancer, is expected to be the first generic approval on the market.

Product Name : Eribulin Mesylate-Generic

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 04, 2024

blank

05

EPSC
Not Confirmed

Details:

Under the agreement, Kexing licenses Eribulin Mesylate Injection, indicated for patients with locally advanced or metastatic breast cancer, from Xiling Lab


Lead Product(s): Eribulin,Inapplicable

Therapeutic Area: Oncology Brand Name: Eribulin Mesylate-Generic

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Kexing Biopharm

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 01, 2024

blank

06

Xiling Lab

China
arrow
EPSC
Not Confirmed

Xiling Lab

China
arrow
EPSC
Not Confirmed

Details : Under the agreement, Kexing licenses Eribulin Mesylate Injection, indicated for patients with locally advanced or metastatic breast cancer, from Xiling Lab

Product Name : Eribulin Mesylate-Generic

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

May 01, 2024

blank

07

MEDSIR

Spain
arrow
EPSC
Not Confirmed

MEDSIR

Spain
arrow
EPSC
Not Confirmed

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

April 12, 2023

blank
  • Development Update

Details:

Undisclosed


Lead Product(s): Eribulin,Inapplicable

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Other Small Molecule

Sponsor: Eisai Inc | Merck & Co

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 17, 2022

blank

08

Australia New Zealand Gynaecological Oncology Group

Country
arrow
EPSC
Not Confirmed

Australia New Zealand Gynaecological Oncology Group

Country
arrow
EPSC
Not Confirmed

Lead Product(s) : Eribulin,Inapplicable

Therapeutic Area : Oncology

Highest Development Status : Phase II

Partner/Sponsor/Collaborator : Eisai Inc | Merck & Co

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 17, 2022

blank

Details:

Halaven (eribulin) is a microtubule dynamics inhibitor in the halichondrin class with a novel mechanism of action, s a simplified and synthetically produced version of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai.


Lead Product(s): Eribulin,Inapplicable

Therapeutic Area: Oncology Brand Name: Halaven

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 09, 2022

blank

09

Eisai

Japan
arrow
EPSC
Not Confirmed

Eisai

Japan
arrow
EPSC
Not Confirmed

Details : Halaven (eribulin) is a microtubule dynamics inhibitor in the halichondrin class with a novel mechanism of action, s a simplified and synthetically produced version of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai.

Product Name : Halaven

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 09, 2022

blank

10

EPSC
Not Confirmed
EPSC
Not Confirmed

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 06, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 441045-17-6 / Eribulin API manufacturers, exporters & distributors?

Eribulin manufacturers, exporters & distributors 1

21

PharmaCompass offers a list of Eribulin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Eribulin manufacturer or Eribulin supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Eribulin manufacturer or Eribulin supplier.

PharmaCompass also assists you with knowing the Eribulin API Price utilized in the formulation of products. Eribulin API Price is not always fixed or binding as the Eribulin Price is obtained through a variety of data sources. The Eribulin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Eribulin

Synonyms

Halaven, Eribulin mesilate, 441045-17-6, Eribulin (mesylate), Eribulin mesylate [usan], Eribulin (as mesylate)

Cas Number

441045-17-6

Unique Ingredient Identifier (UNII)

AV9U0660CW

About Eribulin

Eribulin Mesylate is the mesylate salt of a synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.

Eribulin Manufacturers

A Eribulin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Eribulin, including repackagers and relabelers. The FDA regulates Eribulin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Eribulin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Eribulin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Eribulin Suppliers

A Eribulin supplier is an individual or a company that provides Eribulin active pharmaceutical ingredient (API) or Eribulin finished formulations upon request. The Eribulin suppliers may include Eribulin API manufacturers, exporters, distributors and traders.

click here to find a list of Eribulin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Eribulin USDMF

A Eribulin DMF (Drug Master File) is a document detailing the whole manufacturing process of Eribulin active pharmaceutical ingredient (API) in detail. Different forms of Eribulin DMFs exist exist since differing nations have different regulations, such as Eribulin USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Eribulin DMF submitted to regulatory agencies in the US is known as a USDMF. Eribulin USDMF includes data on Eribulin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Eribulin USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Eribulin suppliers with USDMF on PharmaCompass.

Eribulin JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Eribulin Drug Master File in Japan (Eribulin JDMF) empowers Eribulin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Eribulin JDMF during the approval evaluation for pharmaceutical products. At the time of Eribulin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Eribulin suppliers with JDMF on PharmaCompass.

Eribulin KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Eribulin Drug Master File in Korea (Eribulin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Eribulin. The MFDS reviews the Eribulin KDMF as part of the drug registration process and uses the information provided in the Eribulin KDMF to evaluate the safety and efficacy of the drug.

After submitting a Eribulin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Eribulin API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Eribulin suppliers with KDMF on PharmaCompass.

Eribulin WC

A Eribulin written confirmation (Eribulin WC) is an official document issued by a regulatory agency to a Eribulin manufacturer, verifying that the manufacturing facility of a Eribulin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Eribulin APIs or Eribulin finished pharmaceutical products to another nation, regulatory agencies frequently require a Eribulin WC (written confirmation) as part of the regulatory process.

click here to find a list of Eribulin suppliers with Written Confirmation (WC) on PharmaCompass.

Eribulin NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Eribulin as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Eribulin API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Eribulin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Eribulin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Eribulin NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Eribulin suppliers with NDC on PharmaCompass.

Eribulin GMP

Eribulin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Eribulin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Eribulin GMP manufacturer or Eribulin GMP API supplier for your needs.

Eribulin CoA

A Eribulin CoA (Certificate of Analysis) is a formal document that attests to Eribulin's compliance with Eribulin specifications and serves as a tool for batch-level quality control.

Eribulin CoA mostly includes findings from lab analyses of a specific batch. For each Eribulin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Eribulin may be tested according to a variety of international standards, such as European Pharmacopoeia (Eribulin EP), Eribulin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Eribulin USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty